Europe
According to a study published in Nature Communications on August 11, enzymes that are used by bacteria to break down mucus in the gut can potentially be useful biomarkers for intestinal diseases.
While Russian President Vladimir Putin expressed confidence in the preventative medication against the novel coronavirus, scientists from across the globe expressed concern over the lack of available data.
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
Olorofim is in a Phase IIb study that focuses on rare and resistant life-threatening invasive fungal infections, such as invasive aspergillosis (including azole-resistant strains), scedosporiosis, lomentosporiosis, fusariosis, scopulariopsosis and coccidioidomycosis.
Celleron Therapeutics signed a licensing agreement with Roche for the worldwide rights to cancer drug emactuzumab, a monoclonal antibody directed against colony-stimulating factor 1 (CSF-1R) expressed on macrophages.
The government of Russia has approved a vaccine for COVID-19, marking the first preventative treatment for the novel coronavirus.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 12, 2020.
With a $425 million upfront payment, Bayer bolstered its women’s healthcare pipeline with the acquisition of U.K.-based KaNDy Therapeutics and its investigational treatment for menopause.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 10, 2020.
Intravenous immunoglobulin (IVIG) could be a key to combating seriously ill COVID-19 patients who have been hospitalized due to complications from the disease, and Octapharma AG aims to find out as it assesses the plasma-based treatment in a Phase III study.
PRESS RELEASES